Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of KL0011034 and Alfentanil in Chronic Pain
NCT07710560Phase 1Completed
- Sponsor
- Hunan Kelun Pharmaceutical
- Start
- Jul 2026
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of KL0011034 in chronic pain (3 arms), sponsored by Hunan Kelun Pharmaceutical. Primary endpoint: Number of reported Adverse Events. Started Jul 2026; status: completed.
02
Drugs
KL0011034
03
Conditions
chronic pain
Beyond the preview
Go deeper on NCT07710560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07710560.